: iStockAnalyst.com Symbols Feed

BioMed News Bytes: Antigenics, King, Shire, Delcath

Wed, 21 Oct 2009 14:32:05 GMT

On 6/1/09, Antigenics (NASDAQ: AGEN) announced results of an interim analysis from the Company’s ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46% lower risk of death when treated with Oncophage (vitespen) cancer vaccine compared with observation ([More...]

McKesson (NYSE: MCK): Healthcare Winner

Fri, 16 Oct 2009 14:55:32 GMT

"McKesson (NYSE: MCK), our latest stock of the month, should win no matter how the debate on healthcare reform turns out," says Nathan Slaughter.[More...]

BioMed News Bytes: PGNX, SMTS, ZIOP, CXM, PSDV, BMTI

Wed, 14 Oct 2009 16:31:04 GMT

On 10/14/09, Progenics Pharma (NASDAQ: PGNX) announced a deal with Wyeth to re-acquire all of the worldwide rights to the RELISTOR franchise after a one-year transition period. RELISTOR (subcutaneous injection) is the only drug approved to treat opioid-induced constipation (OIC) in patients with advanced illness receiving palliative care.[More...]

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

New Pain Treatment Triumphs Morphine (OTC:NPHC)

Fri, 11 Sep 2009 16:56:00 GMT

[More...]

The World's Biggest Healthcare Boondoggle Isn't In The U.S.

Fri, 31 Jul 2009 16:26:15 GMT

In June 2006, a Chinese high court reinstated patent protection for Pfizer's erectile dysfunction drug, Viagra. Soon after, the Chinese government committed $500 million to food and drug regulation – more than was spent in the previous seven years combined. Then, in July 2007, Zheng Xiaoyu – China's former head of the State Food and Drug Administration – was executed for taking bribes. These three events signaled China's drug market was finally open for business. And it's the fastest-growing drug market in the world. But here's the catch: It's easy to find drug companies working in China... but not so easy to find ones that will let you profit off the trend. Let me explain... Fueled by a massive aging population, rapid economic development, and urbanization, the pace of China's medical spending over the past five years has been double its[More...]

The Media Is In Flu Frenzy… Here’s How To Invest Amid A Panic

Thu, 30 Apr 2009 21:22:08 GMT

Thursday, April 30, 2009 by Marc Lichtenfeld, Senior Analyst, Smart Profits Report As the Smart Profits Report’s resident health care specialist, you can imagine how many calls and e-mails I’ve received regarding the swine flu outbreak. So here’s my take on the issue - the perspective, the hype, the prevention, and how to deal with the story… Let’s start with the broad public health issue… Flu Facts… And Some Much-Needed Perspective While swine flu is spreading and certainly has potential to become a very serious situation (as does any flu outbreak) if it continues, comparatively speaking, that isn’t the[More...]

Teva: What is Next?

Mon, 23 Mar 2009 13:50:00 GMT

TEVA, the “Generic Giant,” as I once referred to it back in November when I recapped its quarterly earnings, continues to outshine and outclass its peers on pretty much every level. Since I have followed healthcare equities for quite some time now and kept my focus solely on this sector, it is easy for me to say that Teva (TEVA: 43.96, 0.00 (0.00%)) is one of the best managed companies out there, and I think you would agree based on its recent performance and strategic moves. [More...]

Healthcare Isn´t Always Defense

Sun, 22 Mar 2009 21:26:30 GMT

GlaxoSmithKline (GSK) has more than 40% of their income from U.S.. The company produces virtually all categories of drugs and can be described as a direct competitor of companies such as Abbott Laboratories (ABT), Pfizer (PFE), Johnson & Johnson (JNJ), Novartis (NVS) and Sanofi Aventis. The most important segment in terms of sales is

These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements.

[More...]

The Medicines Company Withdraws European Marketing Application for 3-7 Day Daily Dose Oritavancin Therapy

Thu, 20 Aug 2009 20:55:00 GMT

PARSIPPANY, NJ -- -- 08/20/09 -- The Medicines Company today announced the withdrawal of the European marketing authorization application for the 200mg 3-7 day daily dose therapy of oritavancin, its investigational antibiotic drug candidate for the treatment of complicated skin and skin structure infections caused by gram positive pathogens.[More...]

The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 5635

Fri, 14 Aug 2009 21:00:00 GMT

PARSIPPANY, NJ -- -- 08/14/09 -- The Medicines Company announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to four new hires due to additional hiring in connection with its global expansion.[More...]

The Medicines Company Responds to Incorrect News Reports

Mon, 10 Aug 2009 10:55:00 GMT

PARSIPPANY, NJ -- -- 08/10/09 -- The Medicines Company announced today that it had responded to inaccurate implications in a column in The New York Times on August 9, 2009 by Frank Rich and a report that aired on Rachel Maddow's news show on MSNBC on August 6, 2009. The column and report both contained statements that incorrectly created the impression that The Medicines Company has engaged lobbyists to oppose pending healthcare reform legislation and supported efforts to disrupt debate about health care reform. Neither implication is accurate. The Medicines Company has not opposed any of the pending health care reform bills, and has not in any way supported any efforts to disrupt open debate about health care reform. The company's lobbying efforts relate solely to a change in the U.S. patent laws to enable more research, innovation and cost saving in health care. The Medicines Company sincerely hopes that The New York Times and MSNBC, both respected news outlets, will correct their stories.[More...]

The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635

Fri, 31 Jul 2009 20:25:00 GMT

PARSIPPANY, NJ -- -- 07/31/09 -- The Medicines Company announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire due to additional hiring in connection with its global expansion.[More...]

The Medicines Company Reports Second Quarter 2009 Financial Results

Wed, 29 Jul 2009 11:56:00 GMT

PARSIPPANY, NJ -- -- 07/29/09 -- The Medicines Company today announced its financial results for the second quarter of 2009.[More...]

The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor

Thu, 23 Jul 2009 21:55:00 GMT

PARSIPPANY, NJ -- -- 07/23/09 -- The Medicines Company today announced that T. Scott Johnson, M.D. joined the Company on a full-time basis as Vice President, New Business Ventures & Chief Medical Advisor, and has resigned as a director. In his new role, Scott will work to evaluate new product acquisition opportunities and provide medical advice on both marketed and development products in the Company's portfolio.[More...]

The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635

Wed, 15 Jul 2009 20:55:00 GMT

PARSIPPANY, NJ -- -- 07/15/09 -- The Medicines Company announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to ten new hires due to additional hiring in connection with its global expansion.[More...]

The Medicines Company to Announce Second Quarter 2009 Financial Results on Wednesday, July 29, 2009

Wed, 15 Jul 2009 20:25:00 GMT

PARSIPPANY, NJ -- -- 07/15/09 -- The Medicines Company has scheduled its quarterly conference call for Wednesday, July 29, 2009 at 8:30 a.m. Eastern Time to discuss second quarter 2009 financial results and operational developments.[More...]